Shots:

• The P-III BRIGHTE study involves assessing of fostemsavir + OBT vs PBO in 371 patients in a ratio (3:1) with HIV-1 infection who were resistant- intolerable and contraindicated to all ARV in at least four ARV classes
• The P-III BRIGHTE study resulted in increased rates of virologic suppression and immunologic response from 48wks. to 96wks.- @96wks. increase in CD4+ T-cell counts- 67% patients showed CD4 <200 cells/µL to a CD4 ≥200 cells/µL- 56% patients showed CD4 <50 cells/µL increased to a CD4 ≥200 cells/µL
• Fostemsavir is a prodrug of temsavir that binds to the gp120 subunit within the HIV-1 envelope glycoprotein gp160 complex thus preventing the interaction between the virus and cellular CD4 receptors with its expected NDA submission in H2’19

Click here to read full press release/ article | Ref: GSK | Image: POZ